ClinicalTrials.gg
CompletedNCT03724942Updated Sep 19, 2024Results posted

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

A Phase 3 interventional study of Brexpiprazole in Agitation Associated With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Not applicable
Ages
55 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..

Enrollment
8th of 10
164 · median 377
Started
2018
with 1 other
Phase 3
8 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 8 in phase 3, and was the 11th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 55 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dementia by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexpiprazole.

03

Conditions studied

  • Agitation Associated With Dementia of the Alzheimer's Type

Browse trials for

04

Who can participate

Ages eligible
55 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the double-blind treatment period for 10 weeks and all observation, examination and evaluation at Week 10 of the double-blind trial.
  • Patients whose caregiver can properly collect the necessary information.

Exclusion criteria

Exclusion Criteria:

  • Patients who had a serious adverse event which the principal investigator or sub-investigator assessed as related to the investigator product during the double-blind trial.
  • Patients who had delirium during the double-blind trial.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Drug: Brexpiprazole

Interventions

  • Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks

    Also known as: OPC-34712

06

What researchers measure

Primary outcomes

  1. The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)

    This trial enrolled subjects rolled over from Trial 331-102-00088, and the safety of brexpiprazole when administered for a maximum of 24 weeks (including the treatment period of Trial 331-102-00088) was evaluated.

    Time frame: From baseline to week 14

Secondary outcomes

  1. Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing

    The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.

    Time frame: Baseline and 14 weeks after dosing

  2. Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.

    The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.

    Time frame: Baseline and 14 weeks after dosing.

  3. Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing

    The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

    Time frame: 14 weeks after dosing.

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneROLLOVER BREXROLLOVER PLACEBO
Started10262
Completed7344
Not completed2918
Withdrew: Adverse event2014
Withdrew: Lack of efficacy01
Withdrew: Physician decision52
Withdrew: Protocol violation10
Withdrew: Bedridden all day and required full assistance for excretion, meals and change of clothes01
Withdrew: Withdrawal by legal representative30

Outcome measures

PrimaryThe Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)

This trial enrolled subjects rolled over from Trial 331-102-00088, and the safety of brexpiprazole when administered for a maximum of 24 weeks (including the treatment period of Trial 331-102-00088) was evaluated.

Time frame:
From baseline to week 14
Reported as:
Number · Percentage of percipitante
The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)
Percentage of percipitanteROLLOVER BREXROLLOVER PLACEBO
The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs)90.290.3
SecondaryMean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing

The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.

Time frame:
Baseline and 14 weeks after dosing
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing
Units on a scaleROLLOVER BREXROLLOVER PLACEBO
Mean Change From Baseline in Cohen-Mansfield Agitation Inventory (CMAI) Score at 14 Weeks After Dosing-2.5 ± 9.9-6.4 ± 9.3
SecondaryMean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.

The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.

Time frame:
Baseline and 14 weeks after dosing.
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.
Units on a scaleROLLOVER BREXROLLOVER PLACEBO
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 14 Weeks After Dosing.-0.2 ± 0.8-0.4 ± 1.1
SecondaryClinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing

The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

Time frame:
14 weeks after dosing.
Reported as:
Mean · Units on a scale
Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing
Units on a scaleROLLOVER BREXROLLOVER PLACEBO
Clinical Global Impression of Improvement (CGI-I) Score at 14 Weeks After Dosing3.1 ± 1.22.7 ± 1.1

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form through 35 days after last dose of study drug (Up to approximately Week 19). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ROLLOVER BREX0/102 (0%)7/102 (6.9%)90/102 (88.2%)
ROLLOVER PLACEBO1/62 (1.6%)4/62 (6.5%)55/62 (88.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventROLLOVER BREXROLLOVER PLACEBO
Pneumonia aspirationInfections and infestations1/1022/62
Gait disturbanceGeneral disorders2/1020/62
PneumoniaInfections and infestations1/1021/62
Femur fractureInjury, poisoning and procedural complications1/1021/62
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1021/62
Femoral neck fractureInjury, poisoning and procedural complications1/1020/62
Subdural haematomaInjury, poisoning and procedural complications1/1020/62
Blood creatine phosphokinase increasedInvestigations1/1020/62
Muscle rigidityMusculoskeletal and connective tissue disorders1/1020/62
AkathisiaNervous system disorders1/1020/62
Most frequent other events
Showing 10 of 52
Most frequent other events
EventROLLOVER BREXROLLOVER PLACEBO
InsomniaPsychiatric disorders5/10212/62
Sedation complicationNervous system disorders7/1029/62
SomnolenceNervous system disorders13/1027/62
FallInjury, poisoning and procedural complications12/1024/62
Skin abrasionInjury, poisoning and procedural complications11/1022/62
Decreased appetiteMetabolism and nutrition disorders5/1026/62
Extrapyramidal disorderNervous system disorders3/1026/62
Muscle rigidityMusculoskeletal and connective tissue disorders9/1024/62
BradykinesiaNervous system disorders9/1023/62
ContusionInjury, poisoning and procedural complications8/1025/62

Baseline characteristics

This trial was conducted in 164 participants in Japan.

Age, Categorical
Age, Categorical(Participants)ROLLOVER BREXROLLOVER PLACEBOTotal
<=18 years000
Between 18 and 65 years628
>=65 years9660156
Age, Continuous
Age, Continuous(years)ROLLOVER BREXROLLOVER PLACEBOTotal
Mean79.0 ± 6.880.2 ± 6.979.5 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)ROLLOVER BREXROLLOVER PLACEBOTotal
Female6536101
Male372663
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ROLLOVER BREXROLLOVER PLACEBOTotal
Asian10262164
Region of Enrollment
Region of Enrollment(participants)ROLLOVER BREXROLLOVER PLACEBOTotal
Japan10262164
08

Study locations

1 site
  • Jisenkai Nanko Psychiatric Institute
    Shirakawa, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2021, 36 months.

Results were first posted in Sep 2024, 2 years 9 months after primary completion.

Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2018
First posted
Oct 30, 2018
StartActual
Nov 9, 2018
Primary completionActual
Dec 2, 2021
CompletionActual
Jan 5, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03724942
Responsible party
Sponsor
First posted
Oct 30, 2018
Start date
Nov 9, 2018
Primary completion
Dec 2, 2021
Completion
Jan 5, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Osamu Sato
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion